BioPharm Business News

Friday, March 28, 2008
Regeneron’s Arcalyst™ (rilonacept), First and Only FDA-Approved Treatment for Cryopyrin-Associated Periodic Syndromes (CAPS); Now Available in the US
Regeneron Pharmaceuticals, Inc announced that Arcalyst™ (rilonacept) injection for subcutaneous use is now available by prescription in the US for the treatment of cryopyrin-associated periodic syndromes (CAPS)...

Thursday, March 27, 2008
Anacor’s Phase IIa Psoriasis Trial of AN2728 Achieves Primary, Secondary Endpoints 
Anacor Pharmaceuticals, Inc announced positive results from a phase IIa clinical trial of AN2728, a boron-containing inhibitor of phosphodiesterase-4 (PDE4), in patients with psoriasis...

Tuesday, March 25, 2008
UCB Reports That CHMP Upholds Negative Opinion on Cimzia^® (certolizumab pegol) for Crohn’s Disease
The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has rejected UCB's appeal to have Cimzia^® (certolizumab pegol) approved for the treatment of Crohn’s disease patients...

Thursday, March 20, 2008
Merrimack Pharmaceuticals Completes Enrollment in a Phase II Study of MM-093, Recombinant AFP, in Patients With RA
Merrimack Pharmaceuticals, Inc's phase II trial to evaluate the safety and efficacy of MM-093, a nonglycosylated, recombinant version of human alpha-fetoprotein (AFP) in patients suffering from rheumatoid arthritis (RA) has completed enrollment...

Wednesday, March 19, 2008
Centocor, Schering-Plough Submit Marketing Authorization Application Requesting EU Approval of Golimumab to Treat RA, PsA, AS
Centocor, Inc and Schering-Plough Corp are seeking EU approval of golimumab, which targets and neutralizes both the soluble and membrane-bound forms of TNFα, to treat RA, PsA, and AS...

Tuesday, March 18, 2008
Genzyme Reports That US Data From Large Outcome Studies of Carticel^® Support Long-Term Clinical Duration; Prior Marrow Stimulation Techniques May Compromise Treatment With Carticel
Genzyme announced that almost 90% of patients treated with Carticel who experienced improvement in knee function at an early follow-up, sustained their improvement for almost 10 years...